pentobarbital will minimize the level or influence of nateglinide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Check.
pentobarbital decreases amounts of panobinostat by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers can minimize panobinostat stages by ~70% and produce treatment failure.
pentobarbital will decrease the extent or outcome of bexarotene by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will lower the level or result of fludrocortisone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Keep an eye on Closely (one)pentobarbital will reduce the extent or outcome of tadalafil by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
B: Could possibly be acceptable. Possibly animal scientific studies clearly show no possibility but human research not readily available or animal experiments showed insignificant dangers and human scientific tests done and confirmed no hazard.
pentobarbital will minimize the extent or more info influence of capivasertib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong or moderate CYP3A inducers lower capivasertib exposure, which can lower efficacy.
pentobarbital will minimize the extent or outcome of roflumilast by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not advised; strong cytochrome P450 enzyme inducers lessen systemic exposure to roflumilast and may decrease the therapeutic success
pentobarbital will minimize the level or impact of levoketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unknown.
pentobarbital will lower the level or impact of oxybutynin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
Watch Intently (1)pentobarbital will lower the extent or effect of glecaprevir/pibrentasvir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital raises toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on. CYP3A4 inducers might increase the metabolism of ifosfamide to its Lively alkylating metabolites.
pentobarbital will lessen the level or outcome of elbasvir/grazoprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic result of elbasvir/grazoprevir may very well be reduced if coadministered with robust CYP3A inducers which is hence contraindicated.
pentobarbital will decrease the extent or result of bosentan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.